Qiagen CEO Details Companion Dx Strategy and Near-Term Launches at UBS Life Sciences Meeting | GenomeWeb

Originally published Sept. 21.

By Turna Ray

With more than 20 collaborations with drug companies now under its belt, Qiagen is steadily penetrating the companion diagnostics market.

Since acquiring the personalized medicine company DxS in September 2009, Qiagen has netted as many as five new collaborations with drug companies "to develop companion diagnostics for their blockbuster drugs," Qiagen CEO Peer Schatz said at an investor conference this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.